VH-298是一种选择性的VHL（Von Hippel-Lindau）抑制剂（Kd=80-90nM）。
Cas No.:2097381-85-4
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
VH-298 is a selective VHL (Von Hippel-Lindau) inhibitor (Kd=80-90nM). VH-298 stabilizes HIF-α proteins and triggers a hypoxic response by blocking the interaction between VHL and HIF-α proteins. VH-298 can be used in PROTAC (Proteolysis Targeting Chimera) technology and research related to hypoxia signaling pathways[1-4].
In vitro, VH-298 (30-100μM) was used to treat CD4⁺ T cells under Th17-polarizing conditions for 72 hours. VH-298 increased HIF-1α protein levels, simultaneously upregulated IL-17 and GLUT1 expression, and partially restored Th17 cell differentiation[5]. VH-298 (50μM) was used to treat HeLa cells and RPE/mRFP-EGFP-SKL cells for 48 hours. VH-298 significantly promoted peroxisomal degradation (pexophagy), increased ABCD3 ubiquitination, and activated HIF-1α[6].
In vivo, VH-298 (30μM; 100μl; every three days) was locally injected into the wound area of hyperglycemic rats for 21 days. VH-298 improved wound healing, activated the HIF-1 signaling pathway, and promoted vascularization in rats[7]. VH-298 (30μM; 100μl; daily) was injected into the reconstructed attachment site area of a Sprague-Dawley rat model with Achilles tendon-calcaneus rupture. VH-298 improved Achilles tendon-calcaneus healing, increased maximum load and failure energy, and activated the HIF signaling pathway in rats[8].
References:
[1] Frost J, Galdeano C, Soares P, et al. Potent and selective chemical probe of hypoxic signalling downstream of HIF-α hydroxylation via VHL inhibition. Nat Commun. 2016 Nov 4;7:13312.
[2] Ling J, Chen H, Huang M, et al. An mRNA vaccine encoding proteasome-targeted antigen enhances CD8+ T cell immunity. J Control Release. 2025 May 10;381:113578.
[3] Wang Y, Cao Z, Wei Q, et al. VH298-loaded extracellular vesicles released from gelatin methacryloyl hydrogel facilitate diabetic wound healing by HIF-1α-mediated enhancement of angiogenesis. Acta Biomater. 2022 Jul 15;147:342-355.
[4] Qin X, Wu K, Zuo C, et al. The Expression and Role of Hypoxia-induced Factor-1α in Human Tenon's Capsule Fibroblasts under Hypoxia. Curr Eye Res. 2021 Mar;46(3):417-425.
[5] Zhang Q, Wang L, Jiang J, et al. Critical Role of AdipoR1 in Regulating Th17 Cell Differentiation Through Modulation of HIF-1α-Dependent Glycolysis. Front Immunol. 2020 Aug 18;11:2040.
[6] Kim YH, Park NY, Jo DS, et al. Inhibition of VHL by VH298 Accelerates Pexophagy by Activation of HIF-1α in HeLa Cells. Molecules. 2024 Jan 18;29(2):482.
[7] Qiu S, Jia Y, Sun Y, et al. Von Hippel-Lindau (VHL) Protein Antagonist VH298 Improves Wound Healing in Streptozotocin-Induced Hyperglycaemic Rats by Activating Hypoxia-Inducible Factor- (HIF-) 1 Signalling. J Diabetes Res. 2019 Feb 17;2019:1897174.
[8] Qiu S, Jia Y, Tang J, et al. Von Hippel-Lindau (VHL) protein antagonist, VH298, promotes functional activities of tendon-derived stem cells and accelerates healing of entheses in rats by inhibiting ubiquitination of hydroxy-HIF-1α. Biochem Biophys Res Commun. 2018 Nov 10;505(4):1063-1069.
VH-298是一种选择性的VHL（Von Hippel-Lindau）抑制剂（Kd=80-90nM）。VH-298通过阻断VHL与HIF-α蛋白之间的相互作用，稳定HIF-α蛋白并引发低氧反应。VH-298可用于PROTAC（蛋白降解靶向嵌合体）技术以及缺氧信号通路的相关研究[1-4]。
在体外，VH-298（30-100μM）处理Th17极化条件下的CD4⁺ T细胞72小时。VH-298增加HIF-1α蛋白水平，同步上调IL-17和GLUT1表达，并部分恢复Th17细胞分化[5]。VH-298（50μM）处理HeLa细胞及RPE/mRFP-EGFP-SKL细胞48小时。VH-298显著促进过氧化物酶体自噬（pexophagy），同时增加ABCD3泛素化，并激活HIF-1α实现[6]。
在体内，VH-298（30μM；100μl；每三天一次）局部注射于高血糖大鼠的伤口部位21天。VH-298改善了大鼠的伤口愈合、激活了HIF-1信号通路并促进了血管化[7]。VH-298（30μM；100μl；每天一次）注射于跟腱-跟骨断裂的Sprague-Dawley大鼠模型的重建的附着点区域。VH-298改善了大鼠的跟腱-跟骨愈合、增加了最大负荷和破坏能量、并激活了HIF信号通路[8]。
| Cell experiment [1]: | |
Cell lines | HeLa cells (human epithelial immortal cell line) and RPE/mRFP-EGFP-SKL cells (hTERT RPE-1 cells stably expressing monomeric red fluorescent protein‑enhanced green fluorescent protein‑serine‑lysine‑leucine) |
Preparation Method | HeLa cells and RPE/mRFP‑EGFP‑SKL cells were maintained in Dulbecco's minimal essential medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin‑streptomycin at 37 °C under 5% CO₂. Cells were treated with VH-298 (50μM). |
Reaction Conditions | 50μM; 48h |
Applications | VH-298 promoted peroxisomal degradation (pexophagy) in an ATG5‑dependent manner, increased ubiquitination of the peroxisomal membrane protein ABCD3, and required NBR1. VH-298‑induced pexophagy was mediated through activation of HIF‑1α transcriptional activity. |
| Animal experiment [2]: | |
Animal models | Sprague-Dawley rats with streptozotocin-induced hyperglycaemia |
Preparation Method | A full-thickness excisional wound (8mm) was created on the dorsal back of each rat. Rats were treated with VH-298 or PBS by local injection into the wound area every three days. Wound tissues were harvested at postoperative days 7, 14, and 21 for histological analysis. |
Dosage form | 30μM in 100μl; local injection; every three days for 21 days |
Applications | VH-298 treatment accelerated wound healing, improved healing pattern, increased granulation tissue area, enhanced collagen accumulation, promoted angiogenesis (more CD31-positive cell clusters), and activated the HIF-1 signalling pathway (increased HIF-1α, hydroxy-HIF-1α, and VEGF-A positive cells) in the wound area. |
References: | |
| Cas No. | 2097381-85-4 | SDF | |
| Canonical SMILES | O=C([C@H]1N(C([C@H](C(C)(C)C)NC(C2(CC2)C#N)=O)=O)C[C@H](O)C1)NCC3=CC=C(C4=C(C)N=CS4)C=C3 | ||
| 分子式 | C27H33N5O4S | 分子量 | 523.65 |
| 溶解度 | DMSO : ≥ 83.3 mg/mL (159.08 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.9097 mL | 9.5484 mL | 19.0967 mL |
| 5 mM | 381.9 μL | 1.9097 mL | 3.8193 mL |
| 10 mM | 191 μL | 954.8 μL | 1.9097 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.50% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet